Navigation Links
Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors

Chicago, IL (PRWEB) July 25, 2014

Progress in understanding the molecular genetics of brain tumors has ushered in a new era of promising brain tumor treatments, according to Patrick Wen, MD, professor of neurology, Harvard Medical School, director of the Center for Neuro-Oncology, Dana-Farber Cancer Institute.

At the American Brain Tumor Association (ABTA) annual Patient and Family Conference in Chicago, July 25-26, Dr. Wen will moderate a session on how science and new technology are impacting the development of new treatments and advancing strategies to minimize treatment side effects.

“We are getting better at understanding why certain treatments haven’t worked in the past, and we are learning more about the molecular changes that are driving the growth of certain brain tumors, so it’s really an exciting time,” said Dr. Wen. “Unlike lung cancer and other types of leukemia or melanoma where there is one gene that is turned on in most patients, in glioblastomas (GBMs) an aggressive type of malignant brain tumor, there are many genes that are turned on which makes targeted treatments much more complicated.”

The goal of targeted molecular therapies—unlike standard chemotherapy which kills every dividing cell— is to block specific receptors or pathways that are “turned on” just in the tumor. Trials are underway at Harvard and other centers across the country where researchers are examining the genes that are “turned on” since some believe certain genes may be more important targets than others.

“The hope is that this treatment approach would be less toxic and more effective than standard chemotherapy, and we are involved in sophisticated trials where we are trying to match a brain tumor patient’s molecular change to a specific drug designed to target that particular change,” he added.

In just the last 12 months, Dr. Wen says the field has seen significant advances in the potential of immunotherapies, specifically check-point inhibitors.

Crediting immunologists for their work to understand why cancer patients don’t mount an effective immune response, Dr. Wen says, “We are suddenly seeing a lot of excitement in immunotherapy because the same drugs that produced dramatic results for patients with melanoma and lung cancer are now being tested in brain tumor patients.”

Immunotherapy uses the body’s own immune system to attack cancer cells stimulating the immune system to turn against a tumor. The most exciting advances, according to Dr. Wen, is research involving check-point inhibitors which are antibodies that block some of the mechanisms that make the immune system not function as it should. The theory is that if researchers can block these checkpoints, then the body will mount an immune response to attack the cancer cells.

“There is significant momentum surrounding our understanding of the biological differences in tumors from patient to patient,” said Elizabeth M. Wilson, MNA, president & CEO, American Brain Tumor Association. “This research is forming the basis for what will ultimately become a personalized medical approach to treating brain tumors, and the American Brain Tumor Association is proud to be a leader in encouraging and funding innovative approaches like this in brain tumor treatment.”

While it may be years before any of these therapies become integrated into standard treatment, clinical trials are important for advancing medical knowledge and patient care. For more information on clinical trials, go to the ABTA’s TrialConnect® at

The American Brain Tumor Association’s conference annually brings together brain tumor experts, researchers, patients, families and caregivers with the goal of improving the lives of people living with a brain tumor. This year’s theme, “Providing and Pursuing Answers: Advances in Research, Treatment and Care” describes the ABTA’s mission to be a leader in providing and pursuing the answers that brain tumor patients and their families seek. Throughout the conference, renowned brain tumor experts will cover a wide variety of topics covering new research and treatment options and important quality of life issues.

The ABTA’s 2014 patient and family conference will take place July 25-26 at the Renaissance Chicago O’Hare Suites Hotel, just minutes away from Chicago’s O’Hare International Airport. To learn more or register, visit

Founded in 1973, the American Brain Tumor Association was first and is now the only national organization committed to funding brain tumor research and providing support and education programs for all tumor types and all age groups. For more information, visit or call 800-886-ABTA (2282).

About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Boston Children’s Hospital as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Dana-Farber is the top ranked cancer center in New England and fifth nationally, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.

# # #

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
(Date:11/27/2015)... ... , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search ... one of Joplin's most famous and beautiful concert posters. The concert was held on ... Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom was ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
(Date:11/25/2015)... , Nov. 25, 2015 On Tuesday, ... federal bellwether trial against Wright Medical Technology, Inc. ... their Conserve metal-on-metal hip implant device, awarded $11 ... a two week trial and three days of ... hip device was defectively designed and unreasonably dangerous, ...
Breaking Medicine Technology: